on October 9, 2008
Published online before print October 9, 2008, doi: 10.1161/ATVBAHA.108.168757
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 16, 2008
Accepted on September 26, 2008
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice
Frédérique Dol-Gleizes ;
From Sanofi-Aventis R&D (F.D.-G., V.V., A.-M.M., P.S., F.B.), Toulouse, France; and Institut Pasteur de Lille, Département d'Athérosclérose (R.P., P.D., N.H., A.G., B.S.), INSERM U545, Université de Lille 2, Faculté de Pharmacie et de Médecine, Lille, France.
* To whom correspondence should be addressed. E-mail: francoise.bono{at}sanofi-aventis.com.
Objective—The objective of this study was to determine whether the potent selective cannabinoid receptor-1 antagonist rimonabant has antiatherosclerotic properties.
Methods and Results—Rimonabant (50 mg/kg/d in the diet) significantly reduced food intake (from 3.35±.04 to 2.80±0.03 g/d), weight gain (from 14.6±0.7 g to -0.6±0.3 g), serum total cholesterol (from 8.39±0.54 to 5.32±0.18 g/L), and atherosclerotic lesion development in the aorta (from 1.7±0.22 to 0.21±0.037 mm2) and aortic sinus (from 101 000±7800 to 27 000±2900 µm2) of LDLR-/- mice fed a Western-type diet for 3 months. Rimonabant also reduced plasma levels of the proinflammatory cytokines MCP-1 and IL12 by 85% (P<0.05) and 76% (P<0.05), respectively. Pair-fed animals had reduced weight gain (6.2±0.6 g gain), but developed atherosclerotic lesions which were as large as those of untreated animals, showing that the antiatherosclerotic effect of rimonabant is not related to reduced food intake. Interestingly, rimonabant at a lower dose (30 mg/kg/d in the diet) reduced atherosclerosis development in the aortic sinus (from 121 000±20 000 to 62 000±11 000 µm2, 49% reduction, P<0.05), without affecting serum total cholesterol (7.8±0.7 g/L versus 8.1±1.3 g/L in the control group). Rimonabant decreased lipopolysaccharide (LPS)- and IL1
-induced proinflammatory gene expression in mouse peritoneal macrophages in vitro as well as thioglycollate-induced recruitment of macrophages in vivo (10 mg/kg, po bolus).
Conclusions—These results show that rimonabant has antiatherosclerotic effects in LDLR-/- mice. These effects are partly unrelated to serum cholesterol modulation and could be related to an antiinflammatory effect.
Key words: atherosclerosis • rimonabant • obesity • LDLR-deficient mice
Related Article:
- Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns?
- Pál Pacher
Arterioscler Thromb Vasc Biol 2009 29: 7-9.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  S. Immenschuh Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? Cardiovasc Res, October 29, 2009; (2009) cvp339v2. [Full Text] [PDF]
|
|
|
|
|
|
K. H. Han, S. Lim, J. Ryu, C.-W. Lee, Y. Kim, J.-H. Kang, S.-S. Kang, Y. K. Ahn, C.-S. Park, and J. J. Kim CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc Res, September 25, 2009; (2009) cvp240v3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Taskinen ADAGIO-Lipids Gives Promises but Faces the Setbacks Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 339 - 340. [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns? Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 7 - 9. [Full Text] [PDF]
|
|